Adage Capital Partners
ALNY icon

Adage Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Adage Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-84,390
Closed -$27.5M – 877
2025
Q2 		$27.5M Sell
84,390
-197,794
-70% -$54.7M 0.05% 367
2025
Q1 		$76.2M Buy
282,184
+189,128
+203% +$48.6M 0.14% 145
2024
Q4 		$21.9M Sell
93,056
-22,944
-20% -$6.03M 0.04% 423
2024
Q3 		$31.9M Sell
116,000
-138,000
-54% -$35.9M 0.06% 323
2024
Q2 		$61.7M Buy
+254,000
New +$40.1M 0.11% 184
2022
Q4 		– Sell
-485,000
Closed -$97.1M – 978
2022
Q3 		$97.1M Buy
485,000
+315,000
+185% +$60.1M 0.24% 100
2022
Q2 		$24.8M Buy
170,000
+97,700
+135% +$13.9M 0.06% 357
2022
Q1 		$11.8M Sell
72,300
-60,000
-45% -$9.14M 0.02% 649
2021
Q4 		$22.4M Buy
+132,300
New +$24.6M 0.04% 422
2018
Q2 		– Sell
-240,000
Closed -$28.6M – 732
2018
Q1 		$28.6M Sell
240,000
-50,000
-17% -$6.45M 0.07% 324
2017
Q4 		$36.8M Buy
+290,000
New +$36.4M 0.08% 281

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Adage Capital Partners's ALNY Position: Q3 2025 in Review

Adage Capital Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 84,390 shares — an estimated $27.5M sold.

Adage Capital Partners first reported a position in ALNY in Q4 2017 and held it in 11 quarters. The position peaked at $97.1M in Q3 2022. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Adage Capital Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 84,390 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $27.5M.
  • Adage Capital Partners first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • Adage Capital Partners's Alnylam Pharmaceuticals position peaked at $97.1M in Q3 2022.
  • 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.